Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4378965
Author(s) Pollack, Rena M.; Donath, Marc Y.; LeRoith, Derek; Leibowitz, Gil
Author(s) at UniBasel Donath, Marc
Year 2016
Title Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
Journal Diabetes Care
Volume 39 Suppl 2
Pages / Article-Number S244-52
Mesh terms Anti-Inflammatory Agents, therapeutic use; Blood Glucose, metabolism; Cardiovascular Diseases, drug therapy; Diabetes Mellitus, Type 2, drug therapy; Diabetic Angiopathies, drug therapy; Humans; Hyperglycemia, drug therapy; Inflammation, metabolism; Insulin Resistance
Abstract The association between hyperglycemia and inflammation and vascular complications in diabetes is now well established. Antidiabetes drugs may alleviate inflammation by reducing hyperglycemia; however, the anti-inflammatory effects of these medications are inconsistent and it is unknown whether their beneficial metabolic effects are mediated via modulation of chronic inflammation. Recent data suggest that immunomodulatory treatments may have beneficial effects on glycemia, beta-cell function, and insulin resistance. However, the mechanisms underlying their beneficial metabolic effects are not always clear, and there are concerns regarding the specificity, safety, and efficacy of immune-based therapies. Herein, we review the anti-inflammatory and metabolic effects of current antidiabetes drugs and of anti-inflammatory therapies that were studied in patients with type 2 diabetes. We discuss the potential benefit of using anti-inflammatory treatments in diabetes and important issues that should be addressed prior to implementation of such therapeutic approaches.
Publisher American Diabetes Association
ISSN/ISBN 0149-5992 ; 1935-5548
edoc-URL https://edoc.unibas.ch/61691/
Full Text on edoc No
Digital Object Identifier DOI 10.2337/dcS15-3015
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/27440839
ISI-Number WOS:000380742600018
Document type (ISI) Journal Article, Review
 
   

MCSS v5.8 PRO. 0.333 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
30/03/2024